Improving early detection of HCC: The Quest for New Biomarkers [Hosted by NCI]

Improving early detection of HCC: The Quest for New Biomarkers [Hosted by NCI]

July 8 2021
03:00 PM
Webinar series
NIH Research Advancing Hepatitis Elimination
Video URL
NH Webinar 4

Current guidelines (e.g. AASLD) recommend biannual (every 6 months) surveillance for HCC, usually using ultrasound (US) which may or may not include measuring the marker, AFP (alpha-fetoprotein). This is recommended for certain chronic liver diseases (e.g. HBV infected individuals) and also for individuals with cirrhosis. These surveillance recommendations achieve mixed results in their effectiveness for early detection of HCC. There is an unmet need to identify and implement more effective surveillance (e.g. imaging and biomarkers) for the early detection of HCC. This webinar will explore the challenges and opportunities for improving HCC surveillance.


Global Dimension of HCC and Epidemiology- Katherine McGlynn, National Cancer Institute (NCI)

HCC Surveillance Current Practices- Amit Singal, UT Southwestern Medical Center

Biomarkers for HCC- Anand Mehta, Medical University of South Carolina

Risk Assessment of HCC- Nabihah Tayob, Dana-Farber Cancer Institute and Harvard Medical School

Basic HCC Research: Mouse Models- Ray Chung, Massachusetts General Hospital

With introductory remarks from Doug Lowy, Principal Deputy Director at NCI and concluding comments from Anna Lok, University of Michigan and Lewis Roberts, Mayo Clinic